Pain Management Specialist Dr. David Maine Provides Osteocool for Patients
June 27, 2016
Painful metastatic bone tumors affect about 50% of patients with advanced cancers, and up to 30% of patients with spinal metastases receive no relief with radiation, chemotherapy, surgery, etc. Now there is a new device cleared by the U.S. FDA for treating the pain these tumors can cause.
“The OsteoCool device uses high-frequency energy to ablate metastatic spinal tumors to reduce patient pain,” said Dr. David Maine, Director of The Center for Interventional Pain Medicine.
The OsteoCool system uses two water-cooled probes that release heat, but at a controlled lower temperature, to prevent charring. OsteoCool spreads the heat over a region large enough to ablate most metastatic vertebral tumors, as well as any nearby nerve endings that transmit pain signals.
“Temperature-controlled probes are placed through the needles and positioned on either side of the tumor. The temperature is raised for a few minutes, long enough to kill the tumor and any nearby pain sensors, but without harming healthy bone,” Dr. Maine said.
About Mercy
Founded in 1874 in Downtown Baltimore by the Sisters of Mercy, Mercy Medical Center is a 183-licensed bed, acute care, university-affiliated teaching hospital. Mercy has been recognized as a high-performing Maryland hospital (U.S. News & World Report); has achieved an overall 5-Star quality, safety, and patient experience rating (Centers for Medicare and Medicaid Services); is A-rated for Hospital Safety (Leapfrog Hospital Safety Grade); and is certified by the American Nurses Credentialing Center as a Magnet™ hospital. Mercy Health Services is a not-for-profit health system and the parent company of Mercy Medical Center and Mercy Personal Physicians.
Media Contact
Dan Collins, Senior Director of Media Relations
Office: 410-332-9714
Cell: 410-375-7342
Email: dcollins@mdmercy.com